All neonates were operated using a Stöckert S5 Perfusion System (Sorin Group, München, Germany) equipped with roller pumps and a Capiox FX05 oxygenator (Terumo, Tokyo, Japan). Tubing size, cannula size and cannulation strategy were chosen according to the neonate’s size and planned surgery. Total body perfusion bypass flow was calculated to achieve 3.0 L/min/m for neonates weighting ≥ 3.0 kg, and 3.3 L/min/m for neonates weighting < 3.0 kg. For selective cerebral perfusion, bypass flow was reduced to 1/3 of the calculated flow during total body perfusion. RBC salvaging was performed after separation from bypass.
Capiox fx05
Manufactured by Terumo
Sourced in Japan, Belgium
The CAPIOX® FX05 is a blood oxygenator and heat exchanger designed for use in extracorporeal circulation. It is a core component of the cardiopulmonary bypass system used during cardiac surgery.
Automatically generated - may contain errors
Lab products found in correlation
5 protocols using capiox fx05
1
Neonatal Cardiac Bypass Perfusion
2
Cardiopulmonary Bypass Setup for ABO-incompatible Heart Transplant
3
Comparative Evaluation of Pediatric Membrane Oxygenators
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The membrane oxygenators used in this study were commercial membrane oxygenators; oxia® ACF (JMS Co., Ltd., Tokyo, Japan, Sample A), CAPIOX® FX05 (Terumo Co., Ltd., Tokyo, Japan, Sample C), and the newly developed pediatric membrane oxygenator (prototype), and commercial available pediatric membrane oxygenator, which is currently the smallest in the world (LivaNova Co., Ltd., Sorin Group, Mirandola, Italy, Sample B) as a control. Table 1 shows the specifications of the hollow fiber membrane oxygenators. These are the outside blood flow membrane oxygenators.
The membrane specifications of the new pediatric oxygenator and Sample A are exactly the same. The gas permeabilities of the prototype and Sample B membranes are almost the same.
Calculated or ideal retention time is the time that blood is ideally or uniformly perfused once inside a device. The actual retention time is different from the calculated retention time.
The membrane specifications of the new pediatric oxygenator and Sample A are exactly the same. The gas permeabilities of the prototype and Sample B membranes are almost the same.
Calculated or ideal retention time is the time that blood is ideally or uniformly perfused once inside a device. The actual retention time is different from the calculated retention time.
4
Cardiopulmonary Bypass Circuit Setup
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Our standard CPB setup is using a S5 heart-lung bypass machine (Stockert; LivaNova, Munich, Germany), with a mast-mounted single arterial pump (150 mm diameter) and two mast-mounted double-headed pumps (85 mm diameter). These are used for extra-cardiac suction and intra-cardiac venting and haemofiltration. There is also a base-mounted double-headed pump (85 mm diameter) for cardioplegia delivery. As our haemofiltration line arises from the arterial limb of the CPB circuit (Figure 1 ), the haemofiltration pump is slaved to the main arterial pump to prevent cavitation during modified ultrafiltration. For a typical patient of 5 kg undergoing ABO-i heart transplantation, the CPB circuit consists of a tubing set with a 3/16″ arterial line and 1/4″ venous line (LivaNova) with an oxygenator with hardshell venous reservoir (CAPIOX® FX05; Terumo, Leuven, Belgium). The haemofiltration circuit described above takes blood from the arterial line and returns it, via a wye (Y) connector, either to the venous reservoir or, via a 1/8″ line, to the right atrium for modified ultrafiltration as previously described.9
5
Pediatric Cardiopulmonary Bypass Priming
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Priming volume constituted of mannitol 15% (4 ml/kg), 80 ml of albumin 5%, 5 ml of sodium bicarbonate 8.4%, heparin (100 IU/kg), and tranexamic acid (10 mg/kg). Since 2007, the priming volume was reduced from 320 ml to 140–180 ml (Kids D100® Sorin, Italy, CAPIOX FX-05®, Terumo Corporation, Japan). Additional doses of tranexamic acid (10 mg/kg) were given before skin incision and post-CPB after reversal of heparin. Nearly 300 IU/kg heparin was given and CPB was initiated when activated clotting time ACT was ≥400. Target blood heparin concentration was 3 IU/ml (HEPCON, HMS PLUS®, Medtronic, Minneapolis). Eighty milliliter of erythrocyte concentrate was added (hematocrit on CPB 28%–30%). CPB flow was maintained at 2.5 L/m2/min and reduced to 70%–80% when rectal temperature of 28°C–30°C was achieved. Alpha-stat management was used throughout CPB.
Antegrade cardioplegia was administered in dose of 35 ml/kg (St. Thomas Hospital I Solution®, Abbott Laboratories, Chicago, USA). About 30 ml/kg was repeated when cross-clamp was ≥90 min.
Antegrade cardioplegia was administered in dose of 35 ml/kg (St. Thomas Hospital I Solution®, Abbott Laboratories, Chicago, USA). About 30 ml/kg was repeated when cross-clamp was ≥90 min.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!